David Behar, M.D.

entral comparison provides and a second second

206 East Broad Street Bethlehem, PA 18018 Email: <u>dbehar322@gmail.com</u> Cell: 610.389.1716

February 3, 2013

Jane A. Axelrad Associate Director of Policy Food and Drug Administration Rockville, MD 20857

RE: Docket No. FDA-2012-P-0379

Dear Miss Axelrad:

Thank you for your update letter of October 15, 2012. Can you tell me the questions that remain unanswered about my petition in policy, science, or law. The petition has no innovation, and copies the clozapine systems of England and Ireland. Any question requiring real world experience can probably be answered by the officials of those nations. I would try to retrieve any information that would move the petition forward.

Sincerely yours,

1 Belian

David Behar, M.D.

Penet Archal FDA-Centr Brin Eralman Roberte MD 20857 PHILADELFRIA. PA 1931 TO THE ADDRESS OF A In Ithe Industry in the Ist 51 -140 N000N 700 Hagys Ford Rd Penn Valley, PA 19072-1348 **David Behar**